health
grafted neurons that won't connect
Damaged brain tissue cannot be replaced because grafted neurons fail to integrate into existing cortical circuits
Problem statement
Stroke, traumatic brain injury (TBI), and neurodegenerative diseases destroy neocortical tissue — the brain region responsible for cognition, language, motor planning, and personality. Unlike skin, liver, or blood, the adult mammalian neocortex does not regenerate. Lost neurons are not replaced; lost circuits are not rebuilt. The brain's response to injury is scar formation (glial scarring) that walls off damage but prevents new neurons from integrating. Stem cell transplantation into the brain has been attempted, but grafted cells either die, fail to differentiate into the correct neuronal subtypes, or fail to form functional synaptic connections with the host circuit. No therapy exists that can restore lost cognitive function after significant cortical tissue damage.
Why this matters
Stroke is the second leading cause of death worldwide and the third leading cause of death and disability combined: "almost 12 million new strokes each year," over 7 million deaths, "almost 94 million people currently living who have experienced stroke," and over 160 million years of healthy life lost annually (World Stroke Organization Global Stroke Fact Sheet 2025). "Sixty-nine million (95% CI 64–74 million) individuals worldwide are estimated to sustain a TBI each year" (Dewan et al. 2019). Dementia — of which Alzheimer's disease is the most common form, contributing 60–70% of cases — affected 57 million people worldwide in 2021, with nearly 10 million new cases a year (WHO). ARPA-H sizes the U.S. share of the target population at "over 20 million U.S. adults suffering from chronic neocortical brain damage caused by stroke, neurodegeneration, and trauma." Current treatments — physical rehabilitation for stroke/TBI, cholinesterase inhibitors for Alzheimer's — manage symptoms but cannot restore lost tissue or function. "The estimated direct and indirect cost of stroke in the United States was $56.2 billion during 2019–2020" (CDC, MMWR 2024). If cortical tissue could be functionally restored, it would represent the first regenerative therapy for the central nervous system.
What’s been tried and why it hasn’t worked
Neural stem cell transplantation has been tested in animal models and early clinical trials for stroke and TBI. Grafted cells can survive and differentiate into neurons, but they typically form disorganized clusters rather than the precisely layered six-layer cortical architecture required for function. Even when grafted neurons survive, they rarely form long-range connections with distant brain regions — the fiber tract connections that carry information between cortical areas. Organoid transplantation (grafting lab-grown brain organoids into cortex) has shown more promising integration in rodent models: human stem-cell-derived cortical organoids transplanted into the somatosensory cortex of newborn athymic rats matured, received thalamocortical and corticocortical inputs, produced sensory responses in the human cells, extended axons throughout the rat brain, and on optogenetic activation could drive reward-seeking behaviour (Revah O, Gore F, Kelley KW, et al., Nature 2022;610(7931):319–326, doi:10.1038/s41586-022-05277-w). But that work grafted into an intact, developing rodent brain rather than a damaged adult cortex, and organoids still lack the vascular support, layered organization, and regional specification needed for functional contribution to a lesioned circuit. iPSC-derived cortical neurons can be produced in large quantities but delivering them to the correct location, in the correct layer, with the correct connectivity pattern remains unsolved.
What would unlock progress
A method to convert non-neuronal cells already present in the damaged brain (astrocytes, fibroblasts in the scar tissue) into functional cortical neurons in situ — bypassing the need for transplantation — would be a major advance. Alternatively, engineered tissue grafts with pre-organized cortical layer structure, integrated vasculature, and guidance cues that direct axon outgrowth to appropriate targets could provide a transplantable solution. Both approaches require: (1) reliable in vivo or in vitro generation of layer-specific cortical neuron subtypes; (2) methods to promote axon extension from grafted neurons to distant targets through the adult brain's inhibitory environment; (3) assays to verify that grafted tissue is functionally integrated (not just anatomically present) and contributing to cognitive recovery.
Entry points for student teams
A bioengineering team could design a scaffold or microfluidic device that organizes neurons into layered structures mimicking cortical architecture and measures whether layer-specific connectivity patterns emerge, sourcing the cells rather than making them — human iPSC-derived cortical glutamatergic neurons are sold as catalog products (BrainXell's catalog lists eleven cortical glutamatergic lines, and iCell GlutaNeurons recur as a purchased reagent across the human-neuron electrophysiology literature), and primary rodent cortical cultures work too, which keeps the architecture question in the semester instead of the differentiation timeline. A team with no wet lab at all can attack the same bottleneck from public data: the Allen Cell Types Database releases patch-clamp electrophysiology, morphology, and transcriptomics from individual human and mouse cortical neurons with no application or credentialing, so a team can benchmark the firing properties and marker profiles that published iPSC-derived cortical protocols report against native layer-specific neurons and quantify how far the lab-made cells sit from the subtypes a graft would actually need. Deriving layer-5 pyramidal neurons from iPSCs in house is the slowest door and not a facility-free one — it takes a stem-cell culture facility, 60 to 100+ days of differentiation, and someone already fluent in patch-clamp, so approach a stem-cell core or a developmental-neuroscience lab that runs the protocol as routine work. Relevant disciplines: neuroscience, stem cell biology, biomedical engineering, tissue engineering, data science.
Genome — every gene is a door
Structural cousins — same reason stuck, other fields
Sources
ARPA-H, "FRONT — Functional Repair of Neocortical Tissue," program page, ARPA-H, "ARPA-H launches program to restore brain function and return patients to independence," July 10, 2025, Feigin VL, Brainin M, Norrving B, Martins SO, Pandian J, Lindsay P, Grupper MF, Rautalin I. "World Stroke Organization: Global Stroke Fact Sheet 2025." International Journal of Stroke 2025;20(2):132–144, doi:10.1177/17474930241308142, Dewan MC, Rattani A, Gupta S, Baticulon RE, Hung YC, Punchak M, Agrawal A, Adeleye AO, Shrime MG, Rubiano AM, Rosenfeld JV, Park KB. "Estimating the global incidence of traumatic brain injury." Journal of Neurosurgery 2019;130(4):1080–1097, doi:10.3171/2017.10.JNS17352; World Health Organization, "Dementia" fact sheet (updated 3 July 2026), Imoisili OE, Chung A, Tong X, Hayes DK, Loustalot F. "Prevalence of Stroke — Behavioral Risk Factor Surveillance System, United States, 2011–2022." MMWR Morb Mortal Wkly Rep 2024;73(20):449–455, doi:10.15585/mmwr.mm7320a1, Accessed 2026-08-21. go to source 1 ↗ go to source 2 ↗ go to source 3 ↗ go to source 4 ↗ go to source 5 ↗
verification notes (working record)
The collection team’s own sourcing notes for this brief, kept verbatim:
Related briefs: `health-whole-eye-transplant-optic-nerve` (parallel challenge of CNS nerve regeneration — optic nerve is a subset of the broader CNS regeneration problem); `health-bci-implant-longevity-abandonment` (brain-computer interfaces as an alternative to tissue repair for restoring function); `health-tbi-biomarker-clinical-adoption` (TBI diagnostics — upstream of the treatment problem addressed here). The `failure:theoretical-gap` is primary — the science of how to rebuild cortical circuits with correct connectivity in the adult brain is fundamentally incomplete. `temporal:newly-tractable` reflects genuine advances: brain organoid technology (post-2013), in vivo neuronal reprogramming (post-2019), and single-cell transcriptomic atlases of cortical cell types (post-2020) now provide tools that did not exist a decade ago.
Reconciliation 2026-08-21: Both Source-line citations verify — the ARPA-H FRONT program page (full program name "Functional Repair of Neocortical Tissue," https://arpa-h.gov/explore-funding/programs/front) and the press release "ARPA-H launches program to restore brain function and return patients to independence," dated July 10, 2025 (https://arpa-h.gov/news-and-events/arpa-h-launches-program-restore-brain-function-and-return-patients-independence), both fetched and read in full. No fabricated author or venue string was found in this brief; the drift was that every epidemiological number in "Why This Matters" was sourced to nothing but the agency page, and the agency page carries none of them. Corrections: (1) "Stroke is the leading cause of adult disability worldwide, affecting 15 million people per year (5 million deaths, 5 million permanent disability)" is the superseded WHO ~2004 estimate and the disability rank is wrong. Replaced with Feigin VL, Brainin M, Norrving B, Martins SO, Pandian J, Lindsay P, Grupper MF, Rautalin I, "World Stroke Organization: Global Stroke Fact Sheet 2025," International Journal of Stroke 2025;20(2):132–144, doi:10.1177/17474930241308142 (read at https://journals.sagepub.com/doi/10.1177/17474930241308142): almost 12 million new strokes a year, over 7 million deaths, almost 94 million survivors, over 160 million healthy life-years lost; stroke is the second leading cause of death and the third leading cause of death and disability combined, not the first cause of adult disability. (2) "TBI affects 69 million people per year globally" is correct and now carries its source: Dewan MC, Rattani A, Gupta S, Baticulon RE, Hung YC, Punchak M, Agrawal A, Adeleye AO, Shrime MG, Rubiano AM, Rosenfeld JV, Park KB, "Estimating the global incidence of traumatic brain injury," Journal of Neurosurgery 2019;130(4):1080–1097, doi:10.3171/2017.10.JNS17352 — "Sixty-nine million (95% CI 64-74 million) individuals worldwide are estimated to sustain a TBI each year" (record read at https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29701556; the article is often cited as 2018 for its online-ahead-of-print date of April 27, 2018, but the issue of record is 2019;130(4)). (3) "Alzheimer's disease destroys cortical tissue in 55 million people worldwide" conflated the all-cause dementia total with Alzheimer's: WHO's dementia fact sheet (updated 3 July 2026, https://www.who.int/news-room/fact-sheets/detail/dementia) gives 57 million people living with dementia worldwide in 2021 and nearly 10 million new cases a year, with Alzheimer disease "the most common form of dementia" contributing "60–70% of cases." Restated. (4) "The economic burden of stroke alone exceeds $56 billion annually in the U.S." is not an annual figure — CDC's source statement is "The estimated direct and indirect cost of stroke in the United States was $56.2 billion during 2019–2020" (Imoisili OE, Chung A, Tong X, Hayes DK, Loustalot F, MMWR Morb Mortal Wkly Rep 2024;73(20):449–455, doi:10.15585/mmwr.mm7320a1; the cdc.gov page bot-blocks fetches, so the text was read from the PMC mirror at https://pmc.ncbi.nlm.nih.gov/articles/PMC11115433/). Corrected with the year range. (5) ARPA-H's own "over 20 million U.S. adults suffering from chronic neocortical brain damage" added from the press release, attributed to ARPA-H rather than stated as independent epidemiology; ARPA-H's "over a trillion dollars annually" and "$800 billion annually" savings projections were read but left out as program-advocacy figures with no method behind them. (6) The rodent organoid-integration claim was unsourced and slightly overstated: anchored to Revah O, Gore F, Kelley KW, Andersen J, Sakai N, Chen X, Li MY, Birey F, Yang X, Saw NL, Baker SW, Amin ND, Kulkarni S, Mudipalli R, Cui B, Nishino S, Grant GA, Knowles JK, Shamloo M, Huguenard JR, Deisseroth K, Pașca SP, "Maturation and circuit integration of transplanted human cortical organoids," Nature 2022;610(7931):319–326, doi:10.1038/s41586-022-05277-w, with the scope limit that study actually carries (transplant into intact newborn rat somatosensory cortex, not a damaged adult cortex) now stated. Standing caveat for a future pass, recorded here rather than edited into the note above per append-only: the "in vivo neuronal reprogramming (post-2019)" cited as a `temporal:newly-tractable` warrant is contested — PTBP1-knockdown astrocyte-to-neuron conversion failed to replicate under astrocyte-specific lineage tracing in both Parkinson's and Alzheimer's mouse models — Chen W, Zheng Q, Huang Q, Ma S, Li M, "Repressing PTBP1 fails to convert reactive astrocytes to dopaminergic neurons in a 6-hydroxydopamine mouse model of Parkinson's disease," eLife 2022;11:e75636, doi:10.7554/eLife.75636, and Guo T, Pan X, Jiang G, Zhang D, Qi J, Shao L, Wang Z, Xu H, Zhao Y, "Downregulating PTBP1 Fails to Convert Astrocytes into Hippocampal Neurons and to Alleviate Symptoms in Alzheimer's Mouse Models," The Journal of Neuroscience 2022;42(38):7309–7317, doi:10.1523/JNEUROSCI.1060-22.2022 — with AAV leakage into endogenous neurons the leading alternative explanation. The tag is defensible on organoid transplantation and single-cell atlases alone, so it was left as is; genome tags untouched.
Reconciliation 2026-08-21: Entry-point realism repair (`verification/ENTRY-POINT-REALISM-TRIAGE-2026-08-21.md`, score 3). The triage flag is CONFIRMED: the section led with "develop protocols for differentiating iPSCs into specific cortical neuron subtypes (e.g., layer 5 pyramidal neurons) and characterize their electrophysiological properties in vitro," which is a 60–100+ day differentiation run inside a stem-cell culture facility plus PhD-level patch-clamp craft — not a semester door — and the scaffold/microfluidic suggestion that followed silently presumed the same neuron source, so the brief effectively offered zero facility-free doors. Repair: the scaffold/microfluidic arm is kept and now leads, with the cell source decoupled from it — commercial human iPSC-derived cortical glutamatergic neurons or primary rodent cortical cultures — verified against BrainXell's product catalog, which lists seven neuron categories including "Cortical Glutamatergic Neurons (11 products)" (https://brainxell.com/products/); the iCell GlutaNeurons line was verified only indirectly, as 28 Europe PMC full-text records co-mention "iCell GlutaNeurons" and "FUJIFILM" (https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%22iCell%20GlutaNeurons%22%20AND%20%22FUJIFILM%22&format=json), the vendor's own product pages returning HTTP 464 to automated fetches, so the brief credits it as a purchased reagent recurring in the literature rather than asserting a catalog listing. A genuinely facility-free second door was added: benchmarking published iPSC-derived cortical neuron electrophysiology and marker profiles against native layer-specific human and mouse cortical neurons in the Allen Cell Types Database, verified as an open-science resource carrying Patch-seq electrophysiology, morphology, and transcriptomics from human neocortical layers and mouse visual cortex, "openly downloadable without application or credentialing" (https://brain-map.org/cell-types/classes/multimodal-characterization). The in-house iPSC differentiation door is retained as an honest third door with an explicit access line naming what it costs and who owns such access (a stem-cell core or a developmental-neuroscience lab that runs the protocol routinely). No filler door was added; the disciplines line gained data science. Genome tags untouched.